血管生成
碱性成纤维细胞生长因子
血管内皮生长因子
癌症研究
新生血管
体内
生物
血管内皮生长因子A
内皮干细胞
病理
转移
生长因子
免疫学
血管内皮生长因子受体
医学
体外
癌症
受体
遗传学
生物技术
生物化学
作者
K J Kim,B. Li,Jane Winer,Mark Armanini,N. P. Gillett,Heidi S. Phillips,Napoleone Ferrara
出处
期刊:Nature
[Springer Nature]
日期:1993-04-01
卷期号:362 (6423): 841-844
被引量:3444
摘要
The development of new blood vessels (angiogenesis) is required for many physiological processes including embryogenesis, wound healing and corpus luteum formation. Blood vessel neoformation is also important in the pathogenesis of many disorders, particularly rapid growth and metastasis of solid tumours. There are several potential mediators of tumour angiogenesis, including basic and acidic fibroblast growth factors, tumour necrosis factor-alpha and transforming factors-alpha and -beta. But it is unclear whether any of these agents actually mediates angiogenesis and tumour growth in vivo. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and an angiogenesis inducer released by a variety of tumour cells and expressed in human tumours in situ. To test whether VEGF may be a tumour angiogenesis factor in vivo, we injected human rhabdomyosarcoma, glioblastoma multiforme or leiomyosarcoma cell lines into nude mice. We report here that treatment with a monoclonal antibody specific for VEGF inhibited the growth of the tumours, but had no effect on the growth rate of the tumour cells in vitro. The density of vessels was decreased in the antibody-treated tumours. These findings demonstrate that inhibition of the action of an angiogenic factor spontaneously produced by tumour cells may suppress tumour growth in vivo.
科研通智能强力驱动
Strongly Powered by AbleSci AI